Arbeitsgemeinschaft study Internistische Onkologie J
Survival irinotecan versus best advantage supportive care as second-line chemotherapy in gastric cancer--a randomised phase III Arbeitsgemeinschaft study Internistische Onkologie J (AIO) Eur Cancer.
Survival irinotecan versus best advantage supportive care as second-line chemotherapy in gastric cancer--a randomised phase III Arbeitsgemeinschaft study Internistische Onkologie J ( AIO ) Eur Cancer .